How does Mounjaro® differ from other GLP-1 medications?

Mounjaro® (tirzepatide) is unique because it targets not just one, but two incretin hormone receptors—GLP-1 and GIP. Most other medications in this class act only on GLP-1, which helps regulate appetite and blood sugar. By also stimulating the GIP receptor, Mounjaro® enhances the body’s natural ability to manage glucose and may further reduce appetite. This dual-action mechanism has been shown in clinical trials to lead to greater average weight loss compared to single-hormone GLP-1 medications, making it the first therapy of its kind in the metabolic health space.